The Magazine for Sleep Professionals
Friday, May 15, 2026
Resmed announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an individual’s home. OSA, a […]
The Alliance of Sleep Apnea Partners (ASAP) announces the return of Sleep Apnea Education Week, April 18-26, 2025. This annual awareness campaign aims to educate the public about sleep apnea, a serious sleep disorder that affects millions of Americans and has significant implications for both individual health and public health […]
Just a few days ago, an estimated 200 million viewers watched as the Philadelphia Eagles and the Kansas City Chiefs faced off in New Orleans during the biggest game of the National Football League’s season. What many sports fans—and even players—don’t realize is that a significant number of these pro […]
Panthera Dental, a global leader in CAD/CAM implant solutions and dental sleep medical devices, proudly announces the launch of its best-in-class BioMatch System, set to streamline the field of oral appliance therapy (OAT). The BioMatch System is designed to make ordering of a patient-matched appliance an effortless process, ease dental […]
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their sleep disorder. It should be used with […]
Similar to its prevalence in the adult population, obstructive sleep apnea (OSA) in children is one of the most common manifestations of sleep-related breathing disorders. The prevalence of OSA in children has significantly increased in the last 20 years, particularly among the younger population, possibly linked to the rise in […]
LivaNova PLC, a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment […]
While continuous positive airway pressure (CPAP) is still the gold standard treatment for obstructive sleep apnea (OSA), it is well-established that many patients struggle with long-term adherence and tolerance.1 The literature indicates that CPAP non-compliance rates remain as high as 34% with little improvement over the last two decades.2 As […]
EnsoData and Nonin partner to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2® Model 3150 reusable wrist-worn device, offering sleep labs an […]
Incannex Healthcare Inc., a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies, is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). IHL-42X is the Company’s […]
